Intellectual Property partner Robin Silva will participate on the panel for "Strategies for Antibody Patenting in the Wake of Myriad" at ACI's ACI’s Pharmaceutical and Biotechnology Patent Life Cycles and Portfolio Strategies Conference.
Topics to be discussed include:
-
Devising strategies to develop, protect, and enhance antibody therapies
-
Developing a portfolio of antibodies made against known and unknown targets
-
Examining questions of structure, function and obviousness
-
concern of obviousness rejection
-
question of inventive step
-
implications of Myriad
-
Importance of structural non-obviousness for antibodies
-
is there prior art?
-
what of unexpected properties?
-
Structural claiming and drafting strategies relative to antibodies
-
Complying with written description and enablement requirements
-
how does written description apply to functional claims
-
Noelle v. Lederman
-
Ariad v. Lilly
-
Centocor v. Abbott
-
Abbott v. Centocor (IL12), Abbott v. Centocor (TNFalpha)
When:
Thursday, Feb 27, 2014
10:00-11:45 am
Where:
DoubleTree Suites Times Square
New York, NY